Michael May
Algemeen Directeur bij Centre For Commercialization of Regenerative Medicine
Actieve functies van Michael May
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | Directeur/Bestuurslid | - | - |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | Directeur/Bestuurslid | - | - |
Algemeen Directeur | - | - | |
President | - | - | |
20/20 Vision Centers, Inc.
20/20 Vision Centers, Inc. Medical/Nursing ServicesHealth Services 20/20 Vision Centers, Inc. provides lasik surgery services. It offers refractive laser surgery that treats nearsightedness, farsightedness and astigmatism with incisions. It uses technology such as Nidek and Visx Star S3 Laser, Orbscan, and Hansatome Microkeratome. The company is headquartered in Murray, UT. | Directeur/Bestuurslid | - | - |
ExCellThera Ltd. | Voorzitter | - | - |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | Voorzitter | - | - |
CCRM Enterprises Inc | Algemeen Directeur | - | - |
Omniabio, Inc.
Omniabio, Inc. BiotechnologyHealth Technology Omniabio, Inc. is a subsidiary of CCRM and is a contract development and manufacturing organization producing gene-modified cells and viral vectors, compliant with current good manufacturing practices standards. The private company's facility, located at McMaster Innovation Park in Hamilton, Canada, will be the first commercial-scale CDMO dedicated to cell and gene therapies and is expected to be the largest facility of its kind. The company is based in Hamilton, Canada and is supported by the government of Ontario via the Invest Ontario Fund. Omniabio will anchor a biomanufacturing center of excellence and will open in three phases between 2024 and 2026. The CEO of the Canadian company is Mitchel Sivilotti. | Voorzitter | - | - |
Foundation For Cell & Gene Medicine | Directeur/Bestuurslid | - | - |
The Centre for the Commercialization of Antibodies & Biologics
The Centre for the Commercialization of Antibodies & Biologics Pharmaceuticals: MajorHealth Technology The Centre for the Commercialization of Antibodies & Biologics is a Canadian company that manufactures pharmaceutical products. | Directeur/Bestuurslid | - | - |
Loopbaan van Michael May
Eerdere bekende functies van Michael May
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░ | - | ░░░░░░░░░░ | |
░░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░ ░░░░░░░ ░░░░░░░░░ ░░░ ░░░░░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Opleiding van Michael May
University of Toronto | Doctorate Degree |
Statistieken
Internationaal
Canada | 11 |
Verenigde Staten | 5 |
Operationeel
Director/Board Member | 8 |
Chief Executive Officer | 3 |
Chairman | 3 |
Sectoraal
Health Technology | 8 |
Health Services | 3 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Bedrijven in privébezit | 13 |
---|---|
20/20 Vision Centers, Inc.
20/20 Vision Centers, Inc. Medical/Nursing ServicesHealth Services 20/20 Vision Centers, Inc. provides lasik surgery services. It offers refractive laser surgery that treats nearsightedness, farsightedness and astigmatism with incisions. It uses technology such as Nidek and Visx Star S3 Laser, Orbscan, and Hansatome Microkeratome. The company is headquartered in Murray, UT. | Health Services |
Rimon Therapeutics Ltd.
Rimon Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Rimon Therapeutics Ltd. develops and markets pharmaceutical products. The company was founded by Michael May and is headquartered in Mississauga, Canada. | Health Technology |
Toronto Innovation Acceleration Partners
Toronto Innovation Acceleration Partners BiotechnologyHealth Technology Toronto Innovation operates as a commercialization agent. Its technologies disclosed span therapeutics, medical devices and diagnostic imaging, information and communications technologies, and advanced manufacturing and clean technologies. The company was founded by Raphael Hofstein in June 2009 and is headquartered in Toronto, Canada. | Health Technology |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field. | Health Services |
Centre For Commercialization of Regenerative Medicine
Centre For Commercialization of Regenerative Medicine BiotechnologyHealth Technology Centre For Commercialization of Regenerative Medicine supports our partners to develop and commercialize cell and gene therapies and regenerative medicine technologies. Its services include business, technical and facilities. The company is headquartered in Toronto, Canada. | Health Technology |
The Ontario Institute For Regenerative Medicine
The Ontario Institute For Regenerative Medicine Miscellaneous Commercial ServicesCommercial Services The Ontario Institute For Regenerative Medicine provides stem cell and regenerative medicine research services. The company was founded by on November 25, 2014 and is headquartered in Toronto, Canada. | Commercial Services |
AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AgeX Therapeutics, Inc. operates as a biotechnology company, which engages in the development and commercialization of novel therapeutics targeting human aging and degenerative diseases. Its product pipeline includes AGEX-VASC1, AGEX-BAT1, and AGEX-iTR1547. The company was founded by Michael D. West in 2017 and is headquartered in Alameda, CA. | Health Technology |
ExCellThera, Inc.
ExCellThera, Inc. BiotechnologyHealth Technology ExCellThera, Inc. is a world leader in blood stem cell expansion and rejuvenation. The private company is based in Montréal, Canada. The Canadian company's proprietary molecule, UM171, is the standard for hematopoietic stem cell expansion in cell and gene therapy. UM171 has a first-in-class mechanism of action that expands and rejuvenates HSCs, and counteracts exhaustion from culture and gene modification, which are important limitations in cell and gene therapies. ExCellThera has developed commercial GMP grade UM171, which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. ExCellThera was founded in 2013 by Peter Zandstra and Guy Sauvageau. Guy Sauvageau has been the CEO since 2013. | Health Technology |
ExCellThera Ltd. | |
The Centre for the Commercialization of Antibodies & Biologics
The Centre for the Commercialization of Antibodies & Biologics Pharmaceuticals: MajorHealth Technology The Centre for the Commercialization of Antibodies & Biologics is a Canadian company that manufactures pharmaceutical products. | Health Technology |
CCRM Enterprises Inc | |
Omniabio, Inc.
Omniabio, Inc. BiotechnologyHealth Technology Omniabio, Inc. is a subsidiary of CCRM and is a contract development and manufacturing organization producing gene-modified cells and viral vectors, compliant with current good manufacturing practices standards. The private company's facility, located at McMaster Innovation Park in Hamilton, Canada, will be the first commercial-scale CDMO dedicated to cell and gene therapies and is expected to be the largest facility of its kind. The company is based in Hamilton, Canada and is supported by the government of Ontario via the Invest Ontario Fund. Omniabio will anchor a biomanufacturing center of excellence and will open in three phases between 2024 and 2026. The CEO of the Canadian company is Mitchel Sivilotti. | Health Technology |
Foundation For Cell & Gene Medicine |
- Beurs
- Insiders
- Michael May
- Ervaring